Rome V Just Rewrote the Rules for IBS and Gut-Brain Disorder Diagnosis

If you have spent years bouncing between doctors with symptoms that don't fit a neat diagnosis, the Rome V criteria published in May 2026 may be the most consequential update your gastroenterologist has read in a long time. This revision to the internationally recognized diagnostic framework for gut-related conditions is the most substantive overhaul since Rome III in 2006, and it changes how conditions like IBS are defined, who qualifies for a diagnosis, and how clinicians are expected to think about the gut-brain connection.

Key takeaways:

• Rome V drops the stigmatizing "functional" label in favor of Disorders of Gut-Brain Interaction (DGBI), reflecting the real biology behind these conditions.
• The IBS symptom threshold was loosened from one day per week to three days per month, which is expected to raise prevalence estimates back toward historical norms.
• Diet is now formally recognized as central to IBS management, not just a lifestyle footnote.
• Many changes are still making their way into clinical practice, so your doctor may not yet be using the new criteria.

Rome V drops 'functional' label for Disorders of Gut-Brain Interaction

The most symbolic shift in Rome V is terminological, but it carries real weight. The old term "functional GI disorders" has been officially replaced with Disorders of Gut-Brain Interaction (DGBI), a name that reflects the actual mechanisms involved: motility disturbance, visceral hypersensitivity (heightened pain sensitivity in the gut), altered immune function, changes in the gut microbiota, and altered processing in the central nervous system. For patients, this matters because "functional" has long carried an implicit suggestion that symptoms are psychological or not quite real. DGBI signals that the gut-brain axis, the two-way communication network between the digestive system and the brain, is genuinely disrupted in these conditions, not imagined.

The Rome Foundation, which produces these criteria through a modified Delphi consensus process involving multidisciplinary international experts, reviewed a decade of clinical and translational research accumulated since Rome IV was published in 2016. The result is a framework that aims to bridge the gap between how researchers define these disorders and what clinicians actually see in practice.

How Rome V changes who qualifies for an IBS diagnosis

For IBS specifically, two adjustments stand out. First, abdominal discomfort, which had been quietly dropped from Rome IV, has been reintroduced as a qualifying symptom alongside abdominal pain. For people whose dominant experience is discomfort rather than frank pain, this is not a minor tweak. Second, the symptom frequency threshold has been loosened from at least one day per week to at least three days per month. Rome IV's stricter criteria had cut estimated IBS prevalence roughly in half, from around 10% of the population down to about 4%. Rome V's adjustment is expected to bring those numbers back up toward historical figures.

One new exclusion is also worth noting: continuous abdominal pain is now explicitly ruled out of IBS diagnosis. This is designed to sharpen the boundary between IBS and centrally mediated abdominal pain syndrome (CAPS), a separate DGBI in which pain is constant rather than episodic and tied to bowel habits. If your pain never lets up, Rome V steers clinicians toward a different diagnostic category.

Bowel disorders as a whole are now classified into six categories: IBS, Chronic Constipation, Functional Diarrhea, Functional Abdominal Bloating and Distension, Unclassified Bowel Disorder, and a newly added category for Opioid-Induced Constipation (OIC), which acknowledges a common and underdiagnosed drug side effect.

Diet, biofeedback, and anorectal testing get formal clinical recognition

Rome V also formalizes several things that practitioners have known anecdotally for years. Diet is now officially recognized as central to IBS management, not merely a lifestyle consideration. This is significant because it gives clinicians a clearer mandate to discuss dietary approaches, including low-FODMAP protocols and similar strategies, as part of standard care rather than adjunct advice.

On the anorectal side, the new criteria operationalize fecal incontinence and formally define dyssynergic defecation, a condition in which the muscles involved in bowel emptying work against each other, using objective testing rather than symptom description alone. The recognition of rectal hypo- and hypersensitivity as distinct measurable states may guide who benefits from biofeedback therapy, a technique that uses real-time physiological feedback to help patients retrain pelvic floor muscles.

Functional dyspepsia (persistent discomfort centered in the upper abdomen, not explained by structural disease) is better phenotyped in Rome V according to whether symptoms are meal-related, which helps clinicians choose between treatment pathways.

A new clinical tool: the Multidimensional Clinical Profile

One of the most practically significant structural additions in Rome V is the Multidimensional Clinical Profile, or MDCP. Rather than reducing a patient to a single diagnosis code, the MDCP integrates five domains: primary diagnosis, clinical modifiers, impact on quality of life, psychosocial modifiers, and physiological features or biomarkers. This patient-centered assessment model reflects a biopsychosocial approach, recognizing that gut symptoms don't exist in a vacuum and that stress, anxiety, trauma history, and sleep all interact with gut function.

Rome V also formally separates diagnostic criteria into two tracks: one for research and one for clinical use. This addresses a longstanding tension where criteria designed for clean research populations were being applied, imperfectly, to the messier reality of clinical practice.

Adult abdominal migraine and new pediatric categories expand the diagnostic map

Among the more surprising additions is the formal recognition of abdominal migraine in adults. Previous criteria, including Rome IV and the International Classification of Headache Disorders, largely restricted abdominal migraine to children. Rome V extends it to adults, acknowledging that recurring episodes of intense midline abdominal pain, often accompanied by nausea, can occur across the lifespan and deserve their own diagnostic category rather than being lumped under IBS or dismissed.

For children, the pediatric upper GI section has been expanded to include disorders of the esophagus, air-transit disorders, feeding disorders, rumination syndrome, cyclic vomiting syndrome, chronic nausea, and functional dyspepsia. Given that diagnosing gut-brain disorders in children presents distinct challenges due to multifactorial causes and varying symptom presentation across developmental stages, these expanded criteria give pediatric clinicians more specific tools.

Also newly recognized as a distinct clinical entity is retrograde cricopharyngeal dysfunction, better known informally as inability-to-burp syndrome, a condition in which the upper esophageal sphincter fails to relax normally during belching. Its formal inclusion signals a growing clinical recognition that patients presenting with this symptom have a real, treatable disorder.

What Rome V means if you're managing a gut condition right now

The practical implications of Rome V will unfold over the next several years as clinicians update their practice. Research already shows that DGBI prevalence rose significantly after the COVID-19 pandemic, with affected individuals reporting reduced quality of life and higher mood disturbances, meaning the updated criteria are landing at a moment of increased demand for accurate diagnosis. If you have IBS, functional dyspepsia, or any condition previously labeled "functional," it is worth asking your gastroenterologist whether they are applying Rome V criteria and whether the new threshold adjustments or the MDCP framework change anything about your diagnostic picture. The shift toward positive diagnosis based on symptoms, rather than diagnosis by exclusion of organic disease, is particularly meaningful for people who have endured years of tests that ruled things out without offering a clear answer.

Common questions

Does Rome V change my existing IBS diagnosis? Not automatically. If you already have an IBS diagnosis under Rome IV, it is likely to still hold under Rome V. The loosened frequency threshold means some people who didn't qualify before may qualify now. If you've been borderline, it's worth a conversation with your doctor.

What does it mean that diet is now "central" to IBS management? Rome V formally positions dietary intervention as a primary treatment consideration, not an afterthought. This doesn't endorse any single diet, but it does mean clinicians should be discussing dietary approaches, such as low-FODMAP or other strategies, as part of structured care.

Is abdominal migraine in adults newly recognized or newly named? It's newly recognized as a formal adult diagnostic category. The condition itself has been observed clinically, but adults were largely excluded from diagnostic criteria that existed mainly for children. Rome V changes that.

Will my doctor already be using Rome V? Possibly not yet. The criteria were published in May 2026 and implementation into clinical practice takes time. Guidelines, training, and institutional adoption typically lag publication by months to years.

References

1. (2026). Rome V Updates Diagnosis of Gut-Brain Axis Disorders – Medscape. https://www.medscape.com/viewarticle/rome-v-updates-diagnosis-gut-brain-axis-disorders-2026a1000qub
2. Helen Burton‐Murray, Livia Guadagnoli, Kendra Kamp, et al. (2025). Review Article: Rome Foundation Working Team Report: Consensus Statement on the Design and Conduct of Behavioural Clinical Trials for Disorders of Gut–Brain Interaction. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18482
3. Angharad Vernon-Roberts, Mark Safe, Andrew S. Day (2024). Editorial: Pediatric Functional Gastrointestinal Disorders: Challenges in Diagnosis and Treatment. Gastrointestinal Disorders. https://doi.org/10.3390/gidisord6010021
4. Olafur Palsson, Magnus Simren, Ami Sperber, Shrikant Bangdiwala, Johann Hreinsson, Imran Aziz (2025). O28 The prevalence and burden of disorders of gut-brain interaction (DGBI) before versus after the COVID-19 pandemic. Oral Presentations. https://doi.org/10.1136/gutjnl-2025-bsg.28